Needed: A better way to gauge vaccine safety and effectiveness
gooznews.substack.com
There is no shortage of scientists raising legitimate questions about Pfizer’s press release heralding the overwhelming positive results from its COVID-19 vaccine trial. Did the early results reflect a valid sampling of the populations most at risk of contracting the disease: the elderly, minorities and people with chronic medical conditions? Will the reported 90% reduction in disease incidence also reduce hospitalizations and deaths? Will the vaccine confer long-term immunity?
Needed: A better way to gauge vaccine safety and effectiveness
Needed: A better way to gauge vaccine safety…
Needed: A better way to gauge vaccine safety and effectiveness
There is no shortage of scientists raising legitimate questions about Pfizer’s press release heralding the overwhelming positive results from its COVID-19 vaccine trial. Did the early results reflect a valid sampling of the populations most at risk of contracting the disease: the elderly, minorities and people with chronic medical conditions? Will the reported 90% reduction in disease incidence also reduce hospitalizations and deaths? Will the vaccine confer long-term immunity?